We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Capecitabine-cisplatin versus 5-fluorouracil/leucovorin in combination with radiotherapy for adjuvant therapy of lymph node positive locally advanced gastric cancer.
- Authors
Ustaalioğlu, Bala Basak Oven; Bilici, Ahmet; Tilki, Metin; Surmelioglu, Ali; Erkol, Burçak; Figen, Metin; Uyar, Serab; Ustaalioglu, Bala Basak Oven
- Abstract
<bold>Aim Of the Study: </bold>Although surgery is considered to be curative treatment, recurrence rates are high in gastric cancer. Adjuvant 5-fluorouracil (5-FU) based chemoradiotherapy has been shown to improve the prognosis. We compared tolerability and efficacy of the two different chemotherapy regimens; 5-FU/leucovorin (LV) versus cisplatin with capecitabine (XP) combined with radiotherapy (RT) in the adjuvant therapy of the lymph node positive locally advanced gastric cancer.<bold>Materials and Methods: </bold>Totally, 104 patients who underwent curative surgery with lymph node resection were evaluated, respectively. Patients were stratified two group based on the adjuvant chemoradiotherapy regimen. Group 1 (n = 46) received XP followed capecitabine with RT (XRT) then XP. Group 2 (n = 58) received 5-FU/LV combined with RT postoperatively. Two groups were compared based on clinicopathological parameters. Factors related with disease-free survival (DFS) and overall survival (OS) were analyzed.<bold>Results: </bold>Totally, 32 patients had recurrent disease, and there was no difference between two groups. While peritoneal metastasis was more common in XP arm, distant metastasis was commonly seen in 5-FU/LV arm. There was no significant difference between two groups in regard of Grade 3/4 toxicitis; hematologic toxicities were more in 5-FU/LV group than XP arm. In addition, dose modification because of toxicities were more frequent in 5-FU/LV arm (P = 0.003). For all groups, lymph node dissection type was related with DFS, surgical margin and recurrence were important for OS.<bold>Conclusion: </bold>XP-XRT regimen is well tolerated with lower toxicity compared the standard 5-FU/LV-RT. Although there is no difference with respect to outcome, patients with XP arm without the necessity of intravenous catheter admitted hospital less frequent than bolus5-FU/LV arm.
- Subjects
CISPLATIN; ALKYLATING agents; ANTINEOPLASTIC agents; GASTRIC diseases; CANCER treatment
- Publication
Journal of Cancer Research & Therapeutics, 2018, Vol 14, pS736
- ISSN
0973-1482
- Publication type
journal article
- DOI
10.4103/0973-1482.183548